Evidence-based Pharmacotherapy of Allergic Rhinitis

Πηγή: Рецепт. :109-115

Θεματικοί όροι: Н1-антигистаминные препараты, intranasal steroids, меры элиминации, allergic rhinitis, аллергический ринит, cromones, topical anticholinergics, 3. Good health, топические антихолинергические препараты, H1-antihistamines, allergen specific immunotherapy, 03 medical and health sciences, 0302 clinical medicine, avoidance measures, интраназальные стероиды, кромоны, аллерген-специфическая иммунотерапия

Which bronchodilator to choose if a patient with chronic obstructive pulmonary disease continues to smoke? ; Какой бронходилататор выбрать, если пациент с хронической обструктивной болезнью легких продолжает курить?

Συγγραφείς: V. I. Kupaev, D. A. Osipov, В. И. Купаев, Д. А. Осипов

Συνεισφορές: ФГБОУ ВО СамГМУ Минздрава России

Πηγή: PULMONOLOGIYA; Том 31, № 4 (2021); 469-476 ; Пульмонология; Том 31, № 4 (2021); 469-476 ; 2541-9617 ; 0869-0189

Θεματικοί όροι: длительно действующие антихолинергические препараты / длительно действующие β2 -агонисты, nicotine addiction, long-acting muscarinic antagonists, long-acting muscarinic antagonists/ long-acting β2 -agonists, никотиновая зависимость, длительно действующие антихолинергические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/1749/1873; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/1749/686; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/1749/726; GATS. Russian Federation. Global Adult Tobacco Survey: Executive Summary 2016. Available at: https://www.who.int/tobacco/surveillance/survey/gats/gats-2016-rus-exeuctive-summary-En.pdf?ua=1 [Accessed: July 1, 2021].; Stead L.F., Koilpillai P., Fanshawe T.R., Lancaster, T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. 2016; (3): CD008286. DOI:10.1002/14651858.CD008286.pub3.; Płusa T. Quality of life of patients with chronic obstructive pulmonary disease treated with indacaterol and/or glycopyrronium: a real-world Polish observational study. Arch. Med. Sci. Civil. Dis. 2018; 3 (1): e202–209. DOI:10.5114/amscd.2018.81306.; Shahab L., Jarvis M.J., Britton J., West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006; 61 (12): 1043–1047. DOI:10.1136/thx.2006.064410.; Pozo-Rodríguez F., Álvarez C.J., Castro-Acosta A. et al. [Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC Study): method and organisation]. Arch. Bronconeumol. 2010; 46 (7): 349–357. DOI:10.1016/j.arbres.2010.04.004 (in Spanish).; Singh D., Agusti A., Anzueto A. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur. Respir. J. 2019; 53 (5): 1900164. DOI:10.1183/13993003.00164-2019.; Piper M.E., McCarthy D.E., Bolt D.M. et al. Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob. Res. 2008; 10 (6): 1009–1020. DOI:10.1080/14622200802097563.; Moita J., Bárbara C., Cardoso J. et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm. Pharmacol. Ther. 2008; 21 (1): 146–151. DOI:10.1016/j.pupt.2007.04.003.; Tashkin D.P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. 2010; 35 (2): 287–294. DOI:10.1183/09031936.00082909.; Kuusisto K., Knuuttila V., Saarnio P. Pre-treatment expectations in clients: impact on retention and effectiveness in outpatient substance abuse treatment. Behav. Cogn. Psychother. 2011; 39 (3): 257–271. DOI:10.1017/S1352465810000846.; Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6 (5): 337–344. DOI:10.1016/S2213-2600(18)30102-4.; Tashkin D.P., Goodin T., Bowling A. et al. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Respir. Res. 2019; 20 (1):135. DOI:10.1186/s12931-019-1112-0.; Tashkin D.P., Goodin T., Bowling A. et al. Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies. Respir. Med. 2019; 155: 113–120. DOI:10.1016/j.rmed.2019.07.019.; Barrecheguren M., Monteagudo M., Miravitlles M. Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care. NPJ Prim. Care Respir. Med. 2018; 28 (1): 36. DOI:10.1038/s41533-018-0102-x.; Enright P. Don't prescribe tiotropium for smokers with an FEV1 above 60% predicted. Prim. Care Respir. J. 2009; 18 (2): 119–120. DOI:10.3132/pcrj.2009.00014.; Vincken W., Aumann J., Chen H. et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 215–218. DOI:10.2147/COPD.S51592.; Maltais F., Aumann J.L., Kirsten A.M. et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur. Respir. J. 2019; 53 (3): 1802049. DOI:10.1183/13993003.02049-2018.; Maltais F., Hamilton A., Voß F., Maleki-Yazdi M.R. Dose determination for a fixed-dose drug combination: A phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD. Adv. Ther. 2019; 36 (4): 962–968. DOI:10.1007/s12325-019-00911-y; https://journal.pulmonology.ru/pulm/article/view/1749

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/1749
https://doi.org/10.18093/0869-0189-2021-31-4-469-476

Double broncholytic combination of umeclidnium/ vilanterol in COPD therapy: issues of efficacy and safety ; Двойная бронхолитическая комбинация умеклидиния/вилантерола в терапии ХОБЛ: вопросы эффективности и безопасности

Συγγραφείς: N. P. Knyazheskaya, E. Кh. Anaev, A. S. Belevskiy, M. A. Makarova, Н. П. Княжеская, Э. Х. Анаев, А. С. Белевский, М. А. Макарова

Πηγή: Meditsinskiy sovet = Medical Council; № 18 (2022); 49-54 ; Медицинский Совет; № 18 (2022); 49-54 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: вилантерол/умеклидиний, LABA, long-acting β2-agonists, LAMA, long-acting anticholinergic drugs, double bronhodilatation, vilanterol/umeclidinium, длительно действующие β2 -агонисты, длительно действующие антихолинергические препараты, двойная бронходилатация

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7119/6391; Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20.; GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2.; Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. https://doi.org/10.1183/09031936.06.00025805.; Shin S., Bai L., Burnett R.T., Kwong J.C., Hystad P., van Donkelaar A. et al. Air Pollution as a Risk Factor for Incident Chronic Obstructive Pulmonary Disease and Asthma. A 15-Year Population-based Cohort Study. Am J Respir Crit Care Med. 2021;203(9):1138–1148. https://doi.org/10.1164/rccm.201909-1744OC; Wang H.H., Cheng S.L. From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease. Biomedicines. 2021;9(11):1638. https://doi.org/10.3390/biomedicines9111638.; Caramori G., Casolari P., Barczyk A., Durham A.L., Di Stefano A., Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38(4):497–515. https://doi.org/10.1007/s00281-016-0561-5.; Yang W., Li F., Li C., Meng J., Wang Y. Focus on Early COPD: Definition and Early Lung Development. Int J Chron Obstruct Pulmon Dis. 2021;16:3217–3228. https://doi.org/10.2147/COPD.S338359.; Barr R.G., Bluemke D.A., Ahmed F.S., Carr J.J., Enright P.L., Hoffman E.A. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227. https://doi.org/10.1056/nejmoa0808836.; Agusti A., MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68(7):687–690. https://doi.org/10.1136/thoraxjnl-2012-202772.; Soler-Cataluña J.J., Alcázar-Navarrete B., Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397–1405. https://doi.org/10.2147/COPD.S71370.; Soler-Cataluña J.J., Marzo M., Catalán P., Miralles C., Alcazar B., Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719–3731. https://doi.org/10.2147/COPD.S178149.; Miravitlles M., Alcázar B., Soler-Cataluña J.J. The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. Pulmonologiya. 2020;30(2):135–141. https://doi.org/10.18093/0869-0189-2020-30-2-135-141.; Авдеев С.Н., Невзорова В.А., Куделя Л.М., Кондрашова Н.М., Суханова Г.И., Киняйкин М.Ф. и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019;29(3):365–374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374.; Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительной терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;(3):24–32. Режим доступа: https://www.elibrary.ru/item.asp?id=25402705.; Williams D.M., Rubin B.K. Clinical Pharmacology of Bronchodilator Medications. Respir Care. 2018;63(6):641–654. https://doi.org/10.4187/respcare.06051.; Kruse A.C., Li J., Hu J., Kobilka B.K., Wess J. Novel insights into M3 muscarinic acetylcholine receptor physiology and structure. J Mol Neurosci. 2014;53(3):316–323. https://doi.org/10.1007/s12031-013-0127-0.; Miravitlles M., Baek S., Vithlani V., Lad R. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same? Tuberc Respir Dis (Seoul). 2018;81(3):198–215. https://doi.org/10.4046/trd.2018.0040.; Maqsood U., Ho T.N., Palmer K., Eccles F.J., Munavvar M., Wang R. et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):CD012930. https://doi.org/10.1002/14651858.cd012930.pub2.; Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149(5):1181–1196. https://doi.org/10.1016/j.chest.2016.02.646.; Meurs H., Dekkers B.G., Maarsingh H., Halayko A.J., Zaagsma J., Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145–155. https://doi.org/10.1016/j.pupt.2012.07.003.; Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. https://doi.org/10.1016/j.pupt.2010.03.003.; Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. https://doi.org/10.1016/S2213-2600(14)70065-7; Larsson K., Ekberg-Jansson A., Stridsman C., Hanno M., Vanfleteren L.E.G.W. Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease – Results from the Swedish National Airway Register. Int J Chron Obstruct Pulmon Dis. 2021;16:909–918. https://doi.org/10.2147/copd.s300299.; Колонтарева Ю.М., Барабанова Е.Н. Комбинированные бронхолитики в терапии ХОБЛ. Лечащий врач. 2016;(12):85–90. Режим доступа: https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698.; Procopiou P.A., Barrett V.J., Bevan N.J., Biggadike K., Box P.C., Butchers P.R. et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522–4530. https://doi.org/10.1021/jm100326d.; Burkes R.M., Panos R.J. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020;12:589–602. https://doi.org/10.2147/jep.s259328.; Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L. et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. https://doi.org/10.1378/chest.11-2231.; Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–1208. https://doi.org/10.2147/dddt.s39449.; Celli B., Crater G., Kilbride S., Mehta R., Tabberer M., Kalberg C.J., Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. https://doi.org/10.1378/chest.13-1579.; Donohue J.F., Maleki-Yazdi M.R., Kilbride S., Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. https://doi.org/10.1016/j.rmed.2013.06.001.; Maleki-Yazdi M.R., Kaelin T., Richard N., Zvarich M., Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. https://doi.org/10.1016/j.rmed.2014.10.002.; Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(11):2518–2533. https://doi.org/10.1007/s12325-017-0626-4.; Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. https://doi.org/10.1136/thorax.57.10.847.; Makris D., Moschandreas J., Damianaki A., Ntaoukakis E., Siafakas N.M., Milic Emili J., Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101(6):1305–1312.; Kerkhof M., Voorham J., Dorinsky P., Cabrera C., Darken P., Kocks J.W.H. et al. The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. Int J Chron Obstruct Pulmon Dis. 2020;15:1909–1918. https://doi.org/10.2147/copd.s253812.; Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. https://doi.org/10.1183/09031936.00111707.; Jones P.W. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. https://doi.org/10.1081/copd-200050513.; Donohue J.F. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. https://doi.org/10.1081/copd-200053377.; Westwood M., Bourbeau J., Jones P.W., Cerulli A., Capkun-Niggli G., Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12(1):40. https://doi.org/10.1186/1465-9921-12-40.; Singh D., Maleki-Yazdi M.R., Tombs L., Iqbal A., Fahy W.A., Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. https://doi.org/10.2147/copd.s101612.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/7119
https://doi.org/10.21518/2079-701X-2022-16-18-49-54

Experience with the triple fixed combination in patients with chronic obstructive pulmonary disease ; Опыт применения тройной фиксированной комбинации у пациентов с хронической обструктивной болезнью легких

Συγγραφείς: I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina, N. V. Gordeeva, И. В. Демко, М. Г. Мамаева, Е. А. Собко, А. Ю. Крапошина, Н. В. Гордеева

Πηγή: Meditsinskiy sovet = Medical Council; № 21-1 (2021); 80-85 ; Медицинский Совет; № 21-1 (2021); 80-85 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: ингаляционные глюкокортикостероиды, blood eosinophils, long-acting beta-agonists, long-acting anticholinergics, inhaled glucocorticosteroids, эозинофилы крови, длительно действующие β2-агонисты, длительно действующие антихолинергические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6610/5987; Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin D.V., Manakov L.G., Antonini P. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. https://doi. org/10.2147/copd.s67283.; Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М.; 2018. 76 с. Режим доступа: https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf.; Авдеев С.Н. Профилактика обострений хронической обструктивной болезни легких Пульмонология. 2016;26(5):591–603. https://doi.org/10.18093/0869-0189- 2016-26-5-591-603.; Burgel P.R. Des définitions aux phénotypes de BPCO. Presse Med. 2014;43(12 Pt 1): 1337–1343. https://doi.org/10.1016/j.lpm.2014.09.004.; Архипов В.В., Архипова Д.Е., Стукалина Е.Ю., Лазарев А.А. Частота встречаемости отдельных фенотипов хронической обструктивной болезни легких в Российской Федерации, их характеристики и подходы к лечению. Практическая пульмонология. 2016;(3):20–25. Режим доступа: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_3_2016_20.pdf.; Lange P., Halpin D.M., O’Donnell D.E., MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):3– 12. https://doi.org/10.2147/COPD.S85976.; Визель А.А., Визель И.Ю., Бакунина Е.А. Хроническая обструктивная болезнь легких современные подходы к терапии. Медицинский совет. 2016;(15):6–10. https://doi.org/10.21518/2079-701X-2016-15-6-10.; Свидерская Л.Н., Симакова В.М., Демко И.В., Хендогина В.Т., Кудрявцева А.Н., Третьяк Т.В. и др. Сравнительная оценка организации контроля доступности и качества оказания медицинской помощи в условиях краевой консультативной поликлиники. Сибирское медицинское обозрение. 2016;(5):53–64. Режим доступа: https://smr.krasgmu.ru/journal/1629_53.pdf.; Calverley P., Vlies B. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21(4):581–589. https://doi.org/10.1111/resp.12690.; Stockley R.A., Chopra N., Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006;61(2):122–128. https://doi. org/10.1136/thx.2004.033266.; Jones P.W., Bosh T.K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155(4):1283–1289. https://doi.org/10.1164/ ajrccm.155.4.9105068.; Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L. et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. https://doi.org/10.1378/chest.11-2231.; Feldman G., Siler T., Prasad N., Jack D., Piggott S., Owen R. et al. Efficacy and safety of indacaterol 150 microg oncedaily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11. https://doi.org/10.1186/1471-2466-10-11.; Koch A., Pizzichini E., Hamilton A., Hart L., Korducki L., De Salvo M.C. et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat (R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. https://doi.org/10.2147/COPD.S62502.; Dahl R., Chung K.F., Buhl R., Magnussen H., Nonikov V., Jack D. et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. https://doi.org/10.1136/thx.2009.125435.; Korn S., Kerwin E., Atis S., Amos C., Owen R., Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719–726. https://doi.org/10.1016/j.rmed.2011.02.008.; Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W. et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–725. https://doi.org/10.1136/thx.2010.136077.; Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. https://doi.org/10.1056/NEJMoa0805800.; Celli B., Decramer M., Kesten S., Liu D., Mehra S., Tashkin D.P. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–955. https://doi.org/10.1164/ rccm.200906-0876OC.; Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(7):CD009285. https://doi. org/10.1002/14651858.CD009285.pub2.; Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(9):CD009552. https://doi.org/10.1002/14651858.CD009552.pub2.; Celli B., Crater G., Kilbride S., Mehta R., Tabberer M., Kalberg C.J. et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;45(5):981–991. https://doi.org/10.1378/chest.13-1579.; Trivedi R., Richard N., Mehta R., Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81. https://doi. org/10.1183/09031936.00033213.; D’Urzo A., Kerwin E., Overend T., D’Andrea P., Chen H., Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2014;30(3):493–508. https://doi.org/10.1185/03007995. 2013.858618.; Chanez P., Burge P.S., Dahl R., Creemers J., Chuchalin A., Lamarca R. et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23(1):15–21. https://doi.org/10.1016/j.pupt.2009.08.001.; Bateman E.D., Ferguson G.T., Barnes N., Gallagher N., Green Y., Henley M., Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. https://doi.org/10.1183/09031936.00200212.; Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. https://doi.org/10.1016/S2213-2600(14)70065-7.; Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G. et al. Tiotropium and olodaterol fixed-dose combination versus monocomponents in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. https://doi.org/10.1183/09031936.00136014.; Latorre M., Novelli F., Vagaggini B., Braido F., Papi A., Sanduzzi A. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2- agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm Pharmacol Ther. 2015;30:44–50. https://doi. org/10.1016/j.pupt.2014.10.006.; Nannini L.J., Poole P., Milan S.J., Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826. https://doi.org/10.1002/14651858.CD006826.; Spencer S., Evans D.J., Karner C., Cates C.J. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;10:CD007033. https://doi.org/10.1002/14651858.CD007033.; Lipson D.A., Barnacle H., Birk R., Brealey N., Locantore N., Lomas D.A. et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438–446. https://doi.org/10.1164/ rccm.201703-0449OC.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/6610
https://doi.org/10.21518/2079-701X-2021-21-1-80-85

Место фиксированной комбинации индакатерола, гликопиррония и мометазона фуроата в терапии бронхиальной астмы. Заключение Совета экспертов Российского респираторного общества ; The position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society

Συγγραφείς: Aisanov, Zaurbek R., Avdeev, Sergey N., Belevskiy, Andrey S., Vizel', Aleksandr A., Emel'yanov, Aleksandr V., Ignatova, Galina L., Kurbacheva, Oksana M., Leshchenko, Igor' V., Nenasheva, Natal'ya M., Ovcharenko, Svetlana I., Sinopal'nikov, Aleksandr I., Titova, Ol'ga N., Айсанов, З. Р., Авдеев, С.Н., Белевский, А. С., Визель, А. А., Емельянов, А. В., Игнатова, Г. Л., Курбачева, О. М., Лещенко, И. В., Ненашева, Н. М., Овчаренко, С. И., Синопальников, А. И., Титова, О. Н.

Θεματικοί όροι: BRONCHIAL ASTHMA, CONTROL, EXACERBATION, INDACATEROL, GLYCOPYRRONIUM, MOMETASONE, BREEZHALER®, LONG-ACTING Β2-AGONIST/INHALED CORTICOSTEROID, LONG-ACTING ANTICHOLINERGICS, IRIDIUM, ARGON, БРОНХИАЛЬНАЯ АСТМА, КОНТРОЛЬ, ОБОСТРЕНИЕ, ИНДАКАТЕРОЛА АЦЕТАТ, ГЛИКОПИРРОНИЙ, МОМЕТАЗОНА ФУРОАТ, БРИЗХАЛЕР®, ДЛИТЕЛЬНО ДЕЙСТВУЮЩИЕ Β2-АГОНИСТЫ / ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, ДЛИТЕЛЬНО ДЕЙСТВУЮЩИЕ АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ

Περιγραφή αρχείου: application/pdf

Relation: Пульмонология; http://elib.usma.ru/handle/usma/4826

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/4826

The position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society ; Место фиксированной комбинации индакатерола, гликопиррония и мометазона фуроата в терапии бронхиальной астмы. Заключение Совета экспертов Российского респираторного общества

Συγγραφείς: Z. R. Aisanov, S. N. Avdeev, A. S. Belevskiy, A. A. Vizel', A. V. Emel'yanov, G. L. Ignatova, O. M. Kurbacheva, I. V. Leshchenko, N. M. Nenasheva, S. I. Ovcharenko, A. I. Sinopal'nikov, O. N. Titova, З. Р. Айсанов, С. Н. Авдеев, А. С. Белевский, А. A. Визель, А. В. Емельянов, Г. Л. Игнатова, О. М. Курбачева, И. В. Лещенко, Н. М. Ненашева, С. И. Овчаренко, А. И. Синопальников, О. Н. Титова

Συνεισφορές: The Expert Council of the Russian Respiratory Society was held with the support of Novartis Pharma LLC. The representatives of Novartis Pharma LLC did not participate in the writing of this article, are not responsible for the content of the article, and are not responsible for any possible financial or other agreements with any third parties related to this article. The opinion of Novartis Pharma LLC may differ from the opinion of the author of the article and the editorial board., Совет экспертов Российского респираторного общества проведен при поддержке Общества с ограниченной ответственностью «Новартис Фарма». В написании настоящей статьи представители Общества с ограниченной ответственностью «Новартис Фарма» не принимали участия, не несут ответственности за содержание статьи и любые возможные, относящиеся к данной статье договоренности либо финансовые соглашения с любыми третьими лицами. Мнение Общества с ограниченной ответственностью «Новартис Фарма» может отличаться от мнения авторов статьи и редакции.

Πηγή: PULMONOLOGIYA; Том 31, № 1 (2021); 66-74 ; Пульмонология; Том 31, № 1 (2021); 66-74 ; 2541-9617 ; 0869-0189

Θεματικοί όροι: ARGON, control, exacerbation, indacaterol, glycopyrronium, mometasone, Breezhaler®, long-acting β 2 -agonist/inhaled corticosteroid, long-acting anticholinergics, IRIDIUM, контроль, обострение, индакатерола ацетат, гликопирроний, мометазона фуроат, Бризхалер®, длительно действующие β 2 -агонисты / ингаляционные глюкокортикостероиды, длительно действующие антихолинергические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2268/1818; Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990—2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5 (9): 691—706. DOI:10.1016/S2213-2600(17)30293-X.; Chuchalin A., Khaltaev N., Antonov N. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963—974. DOI:10.2147/COPD.S67283.; Global Initiative for Asthma. 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ [Accessed: July 17, 2020].; Stanford R.H., Gilsenan A.W., Ziemiecki R. et al. Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J. Asthma. 2010; 47 (3): 257—262. DOI:10.3109/02770900903584019.; Buhl R., Heaney L.G., Loefroth E. et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting p2-agonist in UK primary care settings. Respir. Med. 2020; 162: 105859. DOI:10.1016/j.rmed.2019.105859.; Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836—844. DOI:10.1164/rccm.200401-033OC.; Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI:10.1038/npjpcrm.2014.23.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: Novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26 (1): 145—155. DOI:10.1016/j.pupt.2012.07.003.; Alagha K., Palot A., Sofalvi T. et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic. Dis. 2014; 5 (2): 85—98. DOI:10.1177/2040622313518227.; Kerstjens H.A.M., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198—207. DOI:10.1056/NEJMoa1208606.; Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2015; (5): CD011721. DOI:10.1002/14651858.CD011721.; Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Once-daily, single-inhaler mometasone—indacaterol—glycopyrronium versus mometasone—indacaterol or twice-daily fluti-casone—salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir. Med. 2020; 8 (10): 1000—1012. DOI:10.1016/S2213-2600(20)30190-9.; Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI:10.1016/j.rmed.2020.106021.; Papi A., Humbert M., Kostikas K. et al. Medium-dose inda-caterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with high-dose indacaterol/mometasone furoate and salmeterol/fluti-casone and reduces exacerbation rates versus high-dose sal-meterol/fluticasone in moderate-to-severe asthma: The IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.; Российское респираторное общество. Бронхиальная астма: Федеральные клинические рекомендации. 2019. Доступно на: http://spulmo.ru/upload/kr_bronhastma_2019.pdf [Дата обращения 17.07.20].; Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042— 1050. DOI:10.1183/09031936.00074905.; Cowie R.L., Giembycz M.A., Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin. Pharmacother. 2009; 10 (12): 2009—2014. DOI:10.1517/14656560903078428.; Donohue J.F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting p2-agonists as monotherapy for chronic obstructive pulmonary disease: a network metaanalysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367381. DOI:10.2147/COPD.S119908.; Blais C.M., Davis B.E., Cockcroft D.W. The effect of gly-copyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir. Res. 2017; 18 (1): 146. DOI:10.1186/s12931-017-0628-4.; Sanders M.J. Guiding inspiratory flow: development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm. Med. 2017; 2017: 1495867. DOI:10.1155/2017/1495867.; Altman P., Wehbe L., Dederichs J. et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm. Med. 2018; 18 (1): 100. DOI:10.1186/s12890-018-0662-0.; Dolovich M.A., Kuttler A., Dimke T.J., Usmani O.S. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. Int. J. Pharm. 2019; 1: 100018. DOI:10.1016/j.ijpx.2019.100018.; Sanduzzi A., Balbo P., Candoli P. et al. COPD: adherence to therapy. Multidiscip. Respir. Med. 2014; 9: 60. DOI:10.1186/2049-6958-9-60.; Price D., Keininger D.L., Viswanad B. et al. Factors associated with appropriate inhaler use in patients with COPD -lessons from the REAL survey [Erratum]. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2253-2254. DOI:10.2147/COPD.S178410.; Визель А.А., Резяпова А.И., Визель И.Ю., Амиров Н.Б. К поиску «идеального» средства доставки лекарственных веществ при обструктивных заболеваниях органов дыхания: наблюдательное исследование в сравнении с данными литературы. Вестник современной клинической медицины. 2020; 13 (2): 22-30. DOI:10.20969/VSKM.2020.13(2).22-30.; Vaidya S.S., Khindri S., Robinson J. et al. Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects. Eur. Respir. J. 2012; 40 (Suppl. 56): 2145. Available at: https://erj.ersjournals.com/content/erj/40/Suppl_56/P2145.full.pdf; Buhl R., Tanase A.M., Hosoe M. et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulm. Pharmacol. Ther. 2020; 62: 101919. DOI:10.1016/j.pupt.2020.101919.; Saini S.D., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care. 2009; 15 (6): e22-33.; Beier J., Watz H., Scholz V. The efficacy of the combination indacaterol/glycopyrronium/mometasone furoate is independent of time of dosing in patients with asthma. Am. J. Respir. Crit. Care Med. 2019; 199: A1277. DOI:10.1164/ajrc-cm-conference.2019.199.1_MeetingAbstracts.A1277.; Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737-1749. DOI:10.1016/S0140-6736(19)32215-9.; Lee L.A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 2021; 9 (1): 69-84. DOI:10.1016/S2213-2600(20)30389-1.; https://journal.pulmonology.ru/pulm/article/view/2268

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/2268
https://doi.org/10.18093/0869-0189-2021-31-1-66-74

A rational approach to the treatment of bronchial asthma in children: what can we do to control the disease? ; Рациональный подход к терапии бронхиальной астмы у детей: что мы можем сделать для контроля заболевания?

Συγγραφείς: N. G. Kolosova, M. D. Shakhnazarova, Н. Г. Колосова, М. Д. Шахназарова

Πηγή: Meditsinskiy sovet = Medical Council; № 1 (2020); 140-144 ; Медицинский Совет; № 1 (2020); 140-144 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2020-1

Θεματικοί όροι: респимат, children, disease control, anticholinergics, m-anticholinergics, M-receptors, tiotropium, Respimat, дети, контроль заболевания, антихолинергические препараты, м-холинолитики, М-рецепторы, тиотропиум

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5550/5060; ReddeL H.K., Pedersen S. (eds.). Global Strategy for Asthma Management and Prevention. 2018. Available at: https://ginasthma.org/wp-content/upLoads/2019/01/2018-GINA.pdf.; Чучалин А.П, Геппе Н.А., Колосова Н.П, Кон-дюрина Е.Г, Малахов А.Б., Мизерницкий Ю.Л., Ревякина В.А. (ред.) Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». М.: Оригиналмакет; 2017. 160 с. Режим доступа: http// astgmu.ru/wp-content/upLoads/2018/10/NatsionaLnaya-programma-BA-u-detej.-Strategiya-Lecheniya-i-profiLaktika.pdf.; Morandi L., BeLLini F., Papi A. Asthma: definition, severity and impact of puLmonary exacerbations. In: BurgeL P.-R., ContoLi M., Lopez-Campos J.L. (eds.) Acute Exacerbations of Pulmonary Diseases (ERS Monograph). SheffieLd, European Respiratory Society; 2017. pp. 1-12.; Nunes C., Pereira A.M., Morais-ALmeida M. Asthma costs and sociaL impact. Asthma Res Pract. 2017;3(1). AvaiLabLe at: https://asthmarp.biomedcentraL.com/articLes/10.1186/s40733-016-0029-3.; Winer R.A., Oin X., Harrington T., Harrington T., Moorman J., Zahran H. Asthma Incidence among ChiLdren and AduLts: Findings from the BehavioraL Risk Factor SurveiLLance System Asthma CaLL-back Survey - United States, 2006-2008. J Asthma. 2012;49(1):16-22. doi:10.3109/02770903.2011.637594.; Chung K.F., WenzeL S.E., Brozek J.L., Bush A., Castro M., Sterk P. J. et aL. InternationaL ERS/ATS guideLines on definition, evaLuation and treatment of severe asthma. Eur Respir J. 2014;43:343-373. doi:10.1183/09031936.00202013.; Custovic A., Johnston S.L., Pavord I., Gaga M., Fabbri L., BeL E.H. et aL. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68(12):1520-1531. doi:10.1111/aLL12275.; Johnston N.W., Sears M.R. Asthma exacerbations 1: EpidemioLogy. Thorax. 2006;61:722-728. doi:10.1136/thx.2005.045161.; Bateman E.D., ReddeL H.K., Eriksson G., Peterson S., OstLund O., Sears M.R. et aL. OveraLL asthma controL: The reLationship between current controL and future risk. J Allergy Clin Immunol. 2010;(3):125:600-608.e6. doi:10.1016/j.jaci.2009.11.033.; Bateman E.D., Bousquet J., Busse W.W., CLark TJ.H., GuL N., Gibbs M. et aL. StabiLity of asthma controL with reguLar treatment: an anaLysis of the Gaining OptimaL Asthma controL (GOAL) study. Allergy. 2008;63(7):932-938. doi:10.1111/j.1398-9995.2008.01724.x.; Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001;10(4):733-740. doi:10.1517/13543784.10.4.733.; Kerstjens H.A., EngeL M., DahL R., Paggiaro P., Beck E., VandewaLker M. et aL. Tiotropium in Asthma PoorLy ControLLed with Standard Combination Therapy. N Engl J Med. 2012;367:1198-1207. doi:10.1056/NEJMoa1208606.; Scott G.D., Fryer A.D. RoLe of Parasympathetic Nerves and Muscarinic Receptors in ALLergy and Asthma. Chem Immunol Allergy. 2012;98:48-69. doi:10.1159/000336498.; Ouizon A., CoLin A.A., PeLosi U., Rossi G.A. Treatment of disorders characterized by reversibLe airway obstruction in chiLdhood: are antichoLinergic agents the answer? Curr Pharm Des. 2012;18(21):3061-3085. doi:10.2174/1381612811209023061.; Ouirce S., Dominguez Ortega J., Barranco P AntichoLinergics for treatment of asthma. J Investig Allergol Clin Immunol. 2015;25(2):84-93. AvaiLabLe at: https//www.ncbi.nLm.nih.gov/pubmed/25997301.; BueLs K.S., Fryer A.D. Muscarinic Receptor Antagonists: Effects on PuLmonary Function. Handbook Exp Pharmacol. 2012;208:317-341. doi:10.1007/978-3-642-23274-9_14.; VogeLberg C., Moroni-Zentgraf P, Leonaviciute-KLimantaviciene M., Sigmund R., HameLmann E., EngeL M., SzefLer S. A randomised dose-ranging study of tiotropium Respimat in chiLdren with symptomatic asthma despite inhaLed corticosteroids. Respir Res. 2015;16:20. doi:10.1186/s12931-015-0175-9.; Bickmann D., Kamin W., Sharma A., WachteL H., Moroni-Zentgraf P., ZieLen S. In Vitro Determination of Respimat Dose DeLivery in ChiLdren: An EvaLuation Based on InhaLation FLow ProfiLes and Mouth-Throat-ModeLs. J Aerosol Med Pulm Drug Deliv. 2016;29(1):76-85. doi:10.1089/jamp.2014.1166.; Kamin W., Frank M., Kattenbeck S., Moroni-Zentgraf P, WachteL H., ZieLen S. A HandLing Study to Assess Use of the Respimat Soft Mist™ InhaLer in ChiLdren Under 5 Years OLd. J Aerosol Med Pulm Drug Deliv. 2015;28(5):372-381. doi:10.1089/jamp.2014.1159.; Геппе Н.А., Колосова Н.Г., Архипов В.В., Мизерницкий Ю.Л., Блохин Б.М., Башкина О.А. и др. Применение тиотропия в базисной терапии бронхиальной астмы у детей. Заключение Совета экспертов Педиатрического респираторного общества. Вопросы практической педиатрии. 2017;12(4):77-84. Режим доступа: http://www.phdynasty.ru/kataLog/zhurnaLy/voprosy-prak-ticheskoy-pediatrii/2017/tom-12-no-mer-4/31631.; VogeLberg С. Emerging roLe of Long-acting antichoLinergics in chiLdren with asthma. Current Opinion in Pulmonary Medicine. 2016;22(1):74-79. doi:10.1097/mcp.0000000000000229.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/5550
https://doi.org/10.21518/2079-701X-2020-1-140-144

Glycopyrronium bromide: clinical efficacy and safety in patients with COPD (a review of clinical trials)

Συγγραφείς: S. Y. Chikina, S. N. Avdeev

Πηγή: Медицинский совет, Vol 0, Iss 16, Pp 18-25 (2015)

Θεματικοί όροι: хроническая обструктивная болезнь легких, фармакотерапия, длительно действующие антихолинергические препараты, гликопиррония бромид, chronic obstructive pulmonary disease, pharmacotherapy, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/399; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/7265eb77171b4c25b7ed0202b1997546

ВЛИЯНИЕ НА ПАРАДИГМУ ПРЕДУПРЕЖДЕНИЯ ОБОСТРЕНИЙ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ ФИКСИРОВАННОЙ КОМБИНАЦИИ ТИОТРОПИЙ/ОЛОДАТЕРОЛ

Θεματικοί όροι: 2. Zero hunger, длительно действующие антихолинергические препараты, exacerbations, shortness of breath, long-acting anticholinergic drugs, одышка, run-in pe-riod, хроническая обструктивная болезнь легких, 3. Good health, run-in период, обострение, chronic obstructive pulmonary disease

Σύνδεσμος πρόσβασης: https://umj.usma.ru/jour/article/view/327

Primenenie M-kholinoblokatorov dlya lecheniya zhenshchin s raznymi tipami nederzhaniya mochi

Συγγραφείς: I A Apolikhina, I S Ibinaeva, A I Zheleznyakova

Πηγή: Гинекология, Vol 10, Iss 1, Pp 52-55 (2008)

Θεματικοί όροι: недержание мочи, м-холиноблокаторы, мочевой пузырь, антихолинергические препараты, Gynecology and obstetrics, RG1-991

Περιγραφή αρχείου: electronic resource

Relation: https://gynecology.orscience.ru/2079-5831/article/view/27922; https://doaj.org/toc/2079-5696; https://doaj.org/toc/2079-5831

Σύνδεσμος πρόσβασης: https://doaj.org/article/07dc236daed14394bac68a025a963d0b

Pharmacoeconomic analysis of treatment with Bretaris Genuair for chronic obstructive pulmonary disease ; Фармакоэкономический анализ применения лекарственного средства Бретарис Дженуэйр в лечении хронической обструктивной болезни легких

Συγγραφείς: A. Yu. Kulikov, E. I. Makarova, А. Ю. Куликов, Е. И. Макарова

Πηγή: PULMONOLOGIYA; Том 25, № 6 (2015); 713-719 ; Пульмонология; Том 25, № 6 (2015); 713-719 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-6

Θεματικοί όροι: анализ затрат, longacting anticholergic agents, aclidinium bromide, Bretaris Genuair, pharmacoeconomics, costeffectiveness analysis, economic impact analysis, cost analysis, длительно действующие антихолинергические препараты, аклидиния бромид, Бретарис Дженуэйр, фармакоэкономика, анализ «затраты – эффективность», анализ «влияния на бюджет»

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/650/580; Краткое руководство по лечению хронической обструктивной болезни легких (ХОБЛ) в амбулаторных условиях (GOLD, пересмотр 2015 г.). Пер. с англ. Под ред. А.С.Белевского. М.: РРО; 2015.; ВОЗ. Хроническая обструктивная болезнь легких (ХОБЛ). URL: http://www.who.int/respiratory/copd/ru; Крысанов И.С. Анализ стоимости хронической обструктивной болезни легких в Российской Федерации. Качественная клиническая практика. 2014; 2: 51–56.; Куликов А.Ю. Комаров И.А. Фармакоэкономическое исследование применения бронхорасширяющих лекарственных средств группы Мхолиноблокаторов (Спирива®) и обструктивной болезни легких. Фармакоэкономика. 2012; 5 (3): 20–26.; Журавков Ю.Л., Королева А.А., Захаренко, А.Г. Тактика ведения пациентов с обострением хронической обструктивной болезни легких. Военная медицина. 2015; 2: 110–114.; Boueri F.M., BucherBartelson B.L., Glenn K.A. et al. Quality of life measured with a generic instrument (Short Form36) improves following pulmonary rehabilitation in patients with COPD. Chest. 2001; 119 (1); 77–84.; Чикина С.Ю., Авдеев С.Н. Новый бронходилататор гликопиррония бромид: обзор клинических исследований. Атмосфера. 2013; 4: 40–46.; Karabis A., Lindner L., Mocarski M. et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: A systematic review and network metaanalysis. Int. J. COPD. 2013; 8: 405–423.; Beier J., Kirsten A.M., Mruz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderatetosevere chronic obstructive pulmonary disease: Results from a 6week, randomized, controlled phase IIIb study. COPD. 2013; 10 (4): 511–522.; Государственный реестр предельных отпускных цен. URL http://grls.rosminzdrav.ru/pricelims.aspx (дата обращения: 01.10.2015).; Приказ Минздравсоцразвития РФ от 23.11.04 № 271 «Об утверждении стандарта медицинской помощи больным хронической обструктивной болезнью легких». URL: www.consultant.ru (дата обращения: 29.09.10).; Приказ Минздрава России от 20.12.12 № 1214н «Об утверждении стандарта первичной медикосанитарной помощи при обострении хронической обструктивной болезни легких». URL: http://garant.ru (дата обращения: 29.09.15).; Приказ Минздравсоцразвития РФ от 11.05.07 № 327 «Об утверждении стандарта медицинской помощи больным с хронической обструктивной болезнью легких (при оказании специализированной помощи)» URL: www.consultant.ru (дата обращения: 29.09.15).; Тарифное соглашение на оплату медицинской помощи, оказываемой по Территориальной программе ОМС г. Москвы на 2015 год. URL http://www. mgfoms.ru/medicinskie*organizacii/tarifi (дата обращения 01.10.2015).; Статистические материалы Минздрава России. Заболеваемость всего населения в 2013 году. М., 2014.; https://journal.pulmonology.ru/pulm/article/view/650

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/650
https://doi.org/10.18093/0869-0189-2015-25-6-713-719

New perspectives in therapy of chronic obstructive pulmonary disease: revolving around aclidinium bromide ; Новые перспективы в лечении хронической обструктивной болезни легких: в фокусе – аклидиния бромид

Συγγραφείς: S. N. Avdeev, N. V. Trushenko, С. Н. Авдеев, Н. В. Трушенко

Πηγή: PULMONOLOGIYA; Том 25, № 6 (2015); 725-735 ; Пульмонология; Том 25, № 6 (2015); 725-735 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-6

Θεματικοί όροι: бронходилатация, anticholinergic agents, chronic obstructive pulmonary disease, bronchodilation, антихолинергические препараты, хроническая обструктивная болезнь легких

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/652/582; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54.; GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2015. Avail able from http://www.goldcopd.org/; Айсанов З.Р., Новиков Ю.К. Антихолинергические препараты в лечении хронической обструктивной болезни легких. Трудный пациент. 2012; 10 (5): 9–13.; Архипов В.В. Клиническая фармакология антихолинергических препаратов Практическая пульмонология. 2014; 2: 32–39.; Ненашева Н.М. Новые возможности достижения контроля астмы с помощью тиотропия бромида. Эффективная фармакотерапия. 2014; 29: 4–13.; Трофименко И.Н., Черняк Б.А. Влияние бронходилататоров на бронхиальную гиперреактивность при хронической обструктивной болезни легких. Сибирский медицинский журнал. 2014; 7: 67–70.; Трофимов В.И. Холинолитики в лечении больных хронической обструктивной болезни легких. Доктор.ру. 2010; 6 (57): 50–53.; Gavalda A., Ramos I., Carcasona C. et al. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm. Pharmacol. Ther. 2014; 28 (2): 114–121.; Milara J., Gabarda E., Gavalda A. et al. An assessment of the functional profile of aclidinium in human bronchi and left atria. Eur. Respir. J. 2011; 38: 859.; Rogliani P., Calzetta L., Ora J. et. al. Pharmacological assessment of the onset of action of aclidinium and glycopy rronium versus tiotropium in COPD patients and human isolated bronchi. Eur. J. Pharmacol. 2015; 761: 383–390.; Ni H., Soe Z., Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014, Sep. 19; CD010509.; De la Motte S., Beier J., Schmid K. et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int. J. Clin. Pharmacol. Ther. 2012; 50 (6): 403–412.; Jansat J.M., Lamarca R., de Miquel G. et al. Safety and pharmacokinetics of single dose of aclidinium bromide, a novel longacting, inhaled antimuscarinic, in healthy subjects. Int. J. Clin. Pharmacol. Ther. 2009; 47 (7): 460–468.; LopezCampos J.L., Calero C., LopezRamirez C. et al. Patientreported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence. 2015; 9: 95–104.; Schmid K., Pascaual S., Garcia Gil. E. et al. Pharma cokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, openlabeled, singledose clinical trial. Clin. Ther. 2010; 32 (10): 1798–1812.; Sun S.X., Mocarski M., Dixit S. et al. Prevalence of renal impairment in COPD patients treated with aclidinium bromide or tiotropium bromide. 10.1164./arjccmconfer ence.2015.191.1._Meeting Abstracts. A5740.; Авдеев С.Н. Базисный препарат для терапии хронической обструктивной болезни легких. Consilium Medicum. 2011; 13 (3): 15–20.; Kerwin E.M., D`Urzo A.D., Gelb A.F. et al. ACCORD I study investigators. Efficacy and safety of 12week treatment with twicedaily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9 (2): 90–101.; Jones P.W., Singh D. Bateman E.D. et al. Efficacy and safety of treatment with twicedaily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830–836.; Rennard S.I., Scanlon P.D., Ferguson G.T. et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12week efficacy and safety of twicedaily aclidinium bromide in chromic obstructive pulmonary disease patients. Clin. Drug Invest. 2013; 33 (12): 893–904.; Gelb A. Tashkin D.P. Make B.J. et al. Longterm safety and efficacy of twicedaily aclidinium bromide in patients with COPD. Respir. Med. 2013; 197 (12): 1957–1965.; D`Urzo A., Kerwin E., Rennard S. et al. Oneyear extension study of ACCORD COPD I: safety and efficacy of two doses of twicedaily aclidinium bromide in patients with COPD. COPD. 2013; 10 (4): 500–510.; Verkindre C., Fukuchi Y., Flemale A. et al. Sustained 24h efficacy of NVA237, a oncedaily longacting muscarinic antagonists, in COPD patients. Respir. Med. 2010; 104 (10): 1482–1489.; Kerwin E.M., Jones P.W., D`Urzo A.D. et al. Efficacy of twicedaily aclidinium bromide 400 mg in subgroups of patients with COPD. Am. J. Crit. Care Med. 2013; 187.1. A4265.; Watz H., Beeh K.M., Magnussen H. et al. Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD. Eur. Respir. J. 2013; 42: 4633.; Santus P., Radovanovic D., Marco F.D. et al. Acute effect of aclidinium bromide on hyperinflation and lung volume distribution in patients with severe COPD. 10.1164./arjccmconference.2015.191.1._Meeting Abstracts. A5736.; Beeh K.M., Watz H., PuenteMastu L. et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation and physical activity in patients with COPD: a randomized, placebocontrolled, crossover trial. BMC Pulm. Med. 2014; 14: 209–221.; Maltais F., Celli B., C`asaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105: 580–587.; McGarvey L., Morice A., Smith J. et al. The effect of twice daily aclidinium bromide on cough and sputum in patients with COPD: results from phase III studies Eur. Respir. J. 2014; 44: 920.; Cortijo J., Mata M., Milara J. et al. Aclidinium inhibits cholinergic and tobacco smokeinduced MUC5AC in human airways. Eur. Respir. J. 2011; 37: 244–254.; Beier J., Kirsten A.M., Mroz R. et al. Efficacy and safety of Aclidinium bromide compared with placebo and Tiotropium in patients with moderate – to – severechronic obstructive pulmonary disease: results from a 6week randomized controlled phase IIIb study. COPD. 2013; 10 (4): 511–522.; Partidge M.R., Karlsson N., Small I.R. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr. Med. Res. Opin. 2009; 25: 2043–2048.; Higgins V., Broomfield S., Pollard R. et al. Impact of morning symptoms on the working lives of COPD patients. Birmingham, UK: International Conference of Chronic Obstructive Pulmonary Disease. 2012. Abstract.; Small M., Broomfield S., Pollard R. et al. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities. Eur. Respir. J. 2012; 40 (56): 3476.; Omachi T.A., Blanc P.D., Claman D.M. et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012; 13 (5): 476–483.; Fuhr R., Magnussen H., Sarem K. et al. Efficacy and safety of aclidinium bromide 400 mg twice daily compared with placebo and tiotripium in patients with moderatetosevere COPD. Chest. 2012; 141: 745–752.; Marth K., Schuller E., Pohl W. Improvements in patient reported outcomes: a prospective, noninterventional study with aclidinium bromide for treatment of COPD. Respir. Med. 2015; 109: 616–624.; Roche N., Chavannes N.H., Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir. Res. 2013; 14: 112–119.; Joos G.F., Schelfhout V.J., Pauwels R.A. et al. Bronchodilatory effects of aclidinium bromide, a longacting muscarinic antagonist, in COPD patients. Respir. Med. 2010; 104 (6): 865–872.; Jones P.W., Rennard S.I., Agusti A. et al. Efficacy and safety of oncedaily aclidinium in chronic obstructive pulmonary disease. Respir. Res. 2011; 12: 55.; Kew K.M., Dias S., Cates C.J. Longacting inhaled therapy (betaagonists, anticholinergics and steroids) for COPD: a network metaanalysis. Cochrane Database Syst. Rev. 2014. DOI:10.1002/14651858.CD010844.pub2.; Mroz R.M., Pilar Ausin M., Lamarca R. et al. Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification. Eur. Respir. J. 2014; 44: 891.; Моисеев С.В. Бронходилататоры при ХОБЛ: длительно действующие антихолинергические препараты или агонисты β2адренорецепторов? Клиническая фармакология и терапия. 2011; 20 (5): 8–10.; Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv. Ther. 2013; 30 (4): 354–368.; Wedzicha J.A., Donaldson G., Chuecos F. et al. Effect of aclidinium bromide on exacerbations in patients with moderate – to severe COPD: pooled analysis of phase III studies. Eur. Respir. J. 2014; 44: 1888.; Oba Y., Lone A.L. Comparative efficacy of longacting musacarinic antagonists in preventing COPD exacebations: a network metaanalysis and metaregression. Ther. Adv. Respir. Dis. 2015; 9 (1): 3–15.; Karabis A., Mocarski M., Eljgelhoven I. et al. Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years. Clin. Econom. Outcom. Res. 2014; 6: 175–185.; Lambers C., Hostettler K., Miglino N. et al. Aclidinium bromide reduces epithelialmesenchymal transition of human COPD epithelial cells. Eur. Respir. J. 2013; 42: 253.; Lambers C., Qi Y., Papakonstantinou E. et al. Aclidinium bromide reduces extracellular matrix deposition by COPD derived mesenchymal cells. Eur. Respir. J. 2013; 42: 3036.; Milara J., Serrano A., Peiro T. et al. Aclidinium inhibits cigarette smokeinduced lung fibroblasttomyofibroblast transition. Eur. Respir. J. 2013; 41: 1264–1274.; Milara J., Peiro T., Peiro T. et al. Effects of aclidinium on cigarette smokeinduced fibroblast activation in vitro. Eur. Respir. J. 2011; 38 (55): 851.; DominguezFandos D., Ferrer E., PuigPey R. et al. Effects of aclidinium bromide in a cigarette smokeexposed Guinea pig model of chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2014; 50 (2): 337–346.; Jones P.W. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Intern. J. COPD. 2015; 10: 677–687.; Newman S.P., Sutton D.J., Segarra R. et al. Lung deposition of aclidinium bromide from Genuair, a multidose drypowder inhaler. Respiration. 2009; 78 (3): 322–328.; Block K., Fyrnys B. Impact of different inhalation volumes on the aerodynamics of aclidinium bromide delivered through the Genuair® inhaler. Am. J. Crit. Care Med. 2010; 181: A4467.; Leidy N.K., Wilcox T.K., Jones P.W. et al. EXACTPRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patientreported diary. Am. J. Resp. Crit. Care Med. 2011; 183 (3): 323–329.; van der Palen J., Ginko T., Kroker A. et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Exp. Opin. Drug Deliv. 2013; 10 (8): 1023–1031.; Donohue J., Rennard S., Celli B. et al. Safety and tolerability of aclidinium bromide in patients with COPD: pooled results from longterm phase III studies. Chest. 2012; 142 (4): 688A.; Lasseter K.C., Aubets J., Chuecos F. et al. Aclidinium bromide, a longacting antimuscarinic, does not affect QT interval in healthy subjects. J. Clin. Pharmacol. 2010; 51 (6): 923–932.; Chapman K.R., Beck E., Alcaide D. et al. Overall and cardiovascular safety of aclidinium bromide in patients with COPD: results of a pooled analysis. Eur. Respir. J. 2014; 44: 893.; https://journal.pulmonology.ru/pulm/article/view/652

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/652
https://doi.org/10.18093/0869-0189-2015-25-6-725-735

A role of fixed combinations of long-acting anticholinergics and long-acting #b2-agonists in therapy of chronic obstructive pulmonary disease ; Значение фиксированных комбинаций длительно действующих антихолинергических препаратов и длительно действующих #b2-агонистов в терапии хронической обструктивной болезни легких

Συγγραφείς: S. N. Avdeev, С. Н. Авдеев

Πηγή: PULMONOLOGIYA; Том 25, № 1 (2015); 93-100 ; Пульмонология; Том 25, № 1 (2015); 93-100 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-1

Θεματικοί όροι: гликопиррония бромид, bronchodilators, fixed combinations, long-acting anticholinergics, long-acting #b2-agonists, indacaterol, glycopyrronium bromide, бронходилататоры, фиксированные комбинации, длительно действующие антихолинергические препараты, длительно действующие #b2-агонисты, индакатерол

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/530/500; GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2014. Available from http://www.goldcopd.org; Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379: 1341–1351.; Hogg J.C., McDonough J.E., Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013; 143: 1436–1443.; Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179–191.; NICE. Clinical Guideline 101. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update issued June 2010). National Institute for Health and Clinical Excellence. 2010. Available from http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf (Last accessed: January 24, 2014).; O'Reilly J., Jones M.M., Parnham J. et al. Guideline Development G. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. Br. Med. J. 2010; 340: 3134.; Rodrigo G.J., Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium (QVA149) for the treatment of COPD: a systematic review. Chest. 2014, 146: 309–317.; Ball D.I., Brittain R.T., Coleman R.A. et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol. 1991; 104: 665–671.; Casarosa P., Bouyssou T., Germeyer S. et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Pharmacol. Exp. Ther. 2009; 330: 660–668.; Borrill Z.L., Houghton C.M., Woodcock A.A. et al. Measuring bronchodilation in COPD clinical trials. Br. J. Clin. Pharmacol. 2005; 59: 379–384.; Renard D., Looby M., Kramer B. et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir. Res. 2011; 12: 54.; Rennard S., Bantje T., Centanni S. et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir. Med. 2008; 102: 1033–1044.; Singh D., Magnussen H., Kirsten A. et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm. Pharmacol. Ther. 2012; 25: 248–253.; Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.; Hanania N.A., Boota A., Kerwin E. et al. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009; 69: 1205–1216.; Tashkin D.P., Littner M., Andrews C.P. et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Med. 2008; 102: 479–487.; Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009; 6: 17–25.; Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir. Med. 2008; 102: 1701–1707.; van Noord J.A., Aumann J.L., Janssens E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006; 129: 509–517.; Mahler D., D’Urzo A., Peckitt C. et al. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am. J. Respir. Crit. Care Med. 2011; 183: A1591.; Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.; Tashkin D.P., Donohue J.F., Mahler D.A. et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 2009; 103: 516–524.; van Noord J.A., Aumann J.L., Janssens E. et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214–222.; van Noord J.A., Aumann J.L., Janssens E. et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir. Med. 2010; 104: 995–1004.; Vogelmeier C., Kardos P., Harari S. et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 2008; 102: 1511–1520.; van Noord J.A., Buhl R., Laforce C. et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65: 1086–1091.; Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003; 58: 659–564.; Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium / vilanterol. Drug Des. Devel. Ther. 2013; 7: 1201–1208.; Bateman E.D., Mahler D.A., Vogelmeier C.F. et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Exp. Rev. Respir. Med. 2014; 8: 357–379.; European Medicine Agency. Ultibro Breezhaler. Available from EMA: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002679/human_med_001691.jsp (accessed October 15, 2014).; Health Canada. Available from Health Canada: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/regist/reg_innov_dr-end.pdf (accessed October 15, 2014).; Dahl R., Chapman K.R., Rudolf M. et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 2013; 107: 1558–1567.; Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 199–209.; Banerji D., Fedele M.J., Chen H., Kim H.J. Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirology. 2013; 18 (Suppl. 4): 1–81.; Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 51–60.; Zhong N., Wang C., Zhou X. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone combination (SFC) in patients with COPD: the LANTERN study. Eur. Respir. J. 2014; 44 (Suppl. 58): P2815.; Beeh K.-M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014; 108: 584–592.; Mahler D.A., Decramer M., D’Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.; Dahl R., Gallagher N., Green Y. et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD. Eur. Respir. J. 2013; 42 (Suppl. 57): 3385.; Dahl R., Jadayel D., Alagappan V.K. et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int. J. COPD. 2013; 8: 501–508.; Ferguson G., Barnes N., Mehta R. Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis [Abstract]. Am. J. Respir. Crit. Care Med. 2013; 187 (1): A1488.; Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir. Med. 2014; 108: 1498–1507.; Pavkov R., Mueller S., Fiebich K. et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr. Med. Res. Opin. 2010; 26: 2527–2533.; Restrepo R.D., Alvarez M.T., Wittnebel L.D. et al. Medication adherence issues in patients treated for COPD. Int. J. COPD. 2008; 3: 371–384.; https://journal.pulmonology.ru/pulm/article/view/530

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/530
https://doi.org/10.18093/0869-0189-2015-25-1-93-100

Anticholinergics for therapy of chronic obstructive pulmonary disease: focus on tiotropium ; Антихолинергические препараты в лечении хронической обструктивной болезни легких: фокус на тиотропий

Συγγραφείς: A. I. Sinopal'nikov, А. И. Синопальников

Πηγή: PULMONOLOGIYA; № 6 (2014); 73-82 ; Пульмонология; № 6 (2014); 73-82 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-0-3

Θεματικοί όροι: тиотропия бромид, bronchodilators, anticholinergics, tiotropium bromide, бронхолитические препараты, антихолинергические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/496/480; Atsou K., Chouaid C., Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe; systematic review. BMC Med. 2011; 9: 7–16. http://www.biomedcentral.com/1741-7015/9/7; Buist A.S., Vollmer W.M., McBumie M.A. Worldwide burden of COPD in highand low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int. J. Tuberc. Lung Dis. 2008; 12: 703–708.; Menezes A.M., Perez-Padilla R., Hallal P.C. et al. Worldwide burden of COPD in highand low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int. J. Tuberc. Lung Dis. 2008; 12: 709–712.; http://www.internationalcod.org; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 12: 963–974.; Aisanov Z., Bai C., Bauerle O. et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int. J. COPD. 2012; 7: 1–12.; O'Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.; Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179–191.; Broncopneumopatia cronica ostruttiva. Linee guida nazionali di riferimento er la prevenzione e la terapia. http:// www.agenas.it/images/agenas/pnlg/BPCO.pdf; Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2014). http://www.goldcopd.com/uploads/users/ files/GOLD_Report_2014_Oct30.pdf; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54. / Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Federal guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).; Ohar J.A., Donohue J.F. Monoand combination theray of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin. Resir. Crit. Care Med. 2010; 31: 321–333.; Johnson M., Rennard S. Alternative mechanisms for longacting beta(2)-adrenergic agonists in COPD. Chest. 2001; 120: 258–270.; Hanania N.A., Moore R.H. Anti-inflammatory activities of beta2-agonists. Cur. Drug Targets Inflam. Allergy. 2004; 3: 271–277.; Bennett W.D., Almond M.A., Zeman K.L. et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm. Pharmacol. Ther. 2006; 19: 96–100.; Profita M., Giorgi R.D., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60: 1361–1369.; CG101 chronic obstructive pulmonary disease (update): full guideline. London: National Institute for Health and Clinical Excellence; 2010. http://guidance.nice.org.uk/ CG101/Guidance; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.; Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 9: CD009157.; Kesten S., Jara M., Wentworth C., Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006; 130: 1695–1703.; Kesten S., Celli B., Decramer M. et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 397–409.; Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource, and cost. Respir. Med. 2011; 105: 435–441.; Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med. J. 1975; 51 (Suppl. 7): 13–20.; Jackson M. "Divine stramonium": the rise and fall of smoking for asthma. Med. Hist. 2010; 54: 171–194.; Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.; Simons F.E. Anticholinergic drugs and the airways: "time future contained in time past". J. Allergy Clin. Immunol. 1987; 80: 239–242.; Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir. Care. 2007; 52: 833–851.; Barnes P.J. The pharmacological properties of tiotropium. Chest. 2000; 117 (2, Suppl.): 63S–66S.; Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136–1142.; Gross N.J., Co E., Skorodin M.S. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989; 96: 984–987.; Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421–425.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26: 145–155.; Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2013; 23: 257–267.; Nardini S., Camiciottoli G., Locicero S. et al. COPD: maximization of bronchodilation. Multidiscip. Respir. Med. 2014; 9: 50–60.; Sykes D.A., Dowling M.R., Leighton-Devies J. et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther. 2012; 343: 520–528.; Disse B., Reichl R., Seck G. et al. Ba 679 BR, a novel longacting anticholinergic bronchodilator. Life Sci. 1993; 52: 537–544.; Casarosa P., Bouyssou T., Germeyer S. et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Harmacol. Exp. Ther. 2009; 330: 660–668.; Haddad E.B., Patel H., Keeling J.E. et al. Pharmacological characterization of the muscarinic recetor anagonists, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol. 1999; 127: 413–420.; Singh D., Leaker B., Tutuneu A. Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD (Abstract). Eur. Respir. J. 2011; 38: 147s.; Verkindre C., Fucuchi Y., Flemale A. et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 2010; 104: 1482–1489.; Breekveldt-Postma N.S., Koerselman J., Erkens J.A. et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 2007; 101: 1398–1405.; Cramer J.A., Bradley-Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14: 25–29.; Beeh K.M., Beier J. The short, the long, and the "ultralong": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010; 27: 150–159.; Taube C., Lehnigk B., Paasch K. et al. Factor analysis of changes in dyspnae and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 216–220.; Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.; O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilator response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 86–94.; Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75–81.; Vincken W., van Noord J.A., Greefhorst A.P. et al. Dutch / Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.; Gauhar U., Dransfield M., Cooper J.A. Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 391–395.; Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317–326.; Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122: 47–55.; Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003; 58: 399–404.; Briggs D.D. Jr, Covelli H., Lapidus R. et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 2005; 18: 397–404.; Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133: 1079–1087.; Tashkin D.P., Celli B., Senn S. et al. for UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.; Anzueto A., Miravitlles M. Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther. Adv. Respir. Dis. 2009; 3: 103–111.; Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 15: 948–955.; Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. COPD. 2008; 4: 229–234.; Burgel P.-R., Paillasseur J.-L., Dusser D. et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir. Res. 2014; 15 (64): 1–10.; Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23: 257–267.; COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. A 85-day multicenter trial. Chest. 1994; 105: 1411–1419.; van Nord J.A., de Munck D.R., Bantje T.A. et al. Longterm treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 2000; 15: 878–885.; Cazzola M., Tashkin D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009; 6: 404–415.; van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21: 101–108.; Mahler D.A., D'Urzo A., Bateman E.D. et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparison. Thorax. 2012; 67: 781–788.; Matera M.G., Rogliani P., Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2014; 15: 961–977.; Aalbers R., Maleki-Yazdi M.R., Hamilton A. et al. Dosefinding study for tiotropium and olodaterol when administration in combination via Resimat inhaler in patients with COPD [abstract]. Eur. Respir. J. 2012; 40: 525–526s.; Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2: 320–325; discussion 340–341.; Singh D., Brooks J., Hagan G. et al. Superiority of "triple" therapy with salmeterol / fluticasone propionate and tiotropium bromide versus in individual components in moderate to severe COPD. Thorax. 2008; 63: 592–598.; Perng D.W., Wu C.C., Su K.C. et al. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006; 11: 598–602.; Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.; Lee T.A., Wilke C., Joo M. et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2009; 169: 1403–1410.; Rodrigo G.J., Plaza V., Casto-Rodriguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Ulm. Pharmacol. Ther. 2012; 25: 40–47.; Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomized clinical trials. Lancet. 2009; 374: 695–703.; Sun S.X., Marynchenko M., Banerjee R. et al. Cost-effectiveness analysis of roflumilast / tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J. Med. Econ. 2011; 14: 805–815.; Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium – the FDA's conclusions. N. Engl. J. Med. 2010; 363: 1097–1099.; Singh S., Loke Y.K., Enright P.L. et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and metaanalysis of randomized controlled trials. Br. Med. J. 2011; 342: d3215.1–9.; Verhamme K., Afonso A., Romio S. et al. Use of tiotropium Respimat SMI versus tiotropium HandiHaler and mortality in patients with COPD. Eur. Respir. J. 2013; 42: 606–615.; Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.; Barnes N.C., Jones P.W., Davis K.J. Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm? Thorax. 2014; 69: 598–599.; Yohanes A.M., Connoly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Intern. J. COPD. 2013; 8: 117–125.; Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547–555.; Powrie D.J., Wilkinson T.M., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Resir. J. 2007; 30: 472–478.; Tonnel A.B., Perez T., Grosbois J.M. et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int. J. COPD. 2008; 3: 301–310.; Reid D.J., Carlson A.A. Clinical use of aclidinium in patients with COPD. Intern. J. COPD. 2014; 9: 369–379.; Donohue J.F., Niewoehner D., Brooks J. et al. Safety and tolerability of once-daily umeclidinium / vilanterol 125 / 25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir. Res. 2014; 15: 78–86.; Kerwin E.M., D'Urzo A.D., Gelb A.F. et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9: 90–101.; Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830–836.; D'Urzo A.D., Ferguson G.T., van Noord J.A. et al. Efficacy and safety of once-daily NVA237 in patients with moderateto-severe COPD: the GLOW1 trial. Respir. Res. 2011; 12: 156–163.; https://journal.pulmonology.ru/pulm/article/view/496

Διαθεσιμότητα: https://journal.pulmonology.ru/pulm/article/view/496
https://doi.org/10.18093/0869-0189-2014-0-6-73-82

Клиническая фармакология антихолинергических препаратов

Συγγραφείς: Архипов, Владимир

Θεματικοί όροι: АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ,БРОНХИАЛЬНАЯ АСТМА,ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/klinicheskaya-farmakologiya-antiholinergicheskih-preparatov-1
http://cyberleninka.ru/article_covers/15719028.png

Клиническая фармакология антихолинергических препаратов

Συγγραφείς: Владимир, Владимирович

Θεματικοί όροι: антихолинергические препараты, бронхиальная астма, хроническая обструктивная болезнь легких

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/klinicheskaya-farmakologiya-antiholinergicheskih-preparatov
http://cyberleninka.ru/article_covers/15687210.png

СОВРЕМЕННЫЙ ВЗГЛЯД НА ВКЛЮЧЕНИЕ АНТИХОЛИНЕРГИЧЕСКИХ ПРЕПАРАТОВ В СОСТАВ ПРЕМЕДИКАЦИИ

Συγγραφείς: Толасов, Константин, Петрова, Ж., Острейков, И.

Θεματικοί όροι: АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ, АТРОПИН, ПРЕМЕДИКАЦИЯ, БРАДИКАРДИЯ, НАРУШЕНИЯ СЕРДЕЧНОГО РИТМА, САЛИВАЦИЯ, АNTICHOLINERGICS

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sovremennyy-vzglyad-na-vklyuchenie-antiholinergicheskih-preparatov-v-sostav-premedikatsii
http://cyberleninka.ru/article_covers/15797263.png

Патогенетическое значение транскраниальной электростимуляции в комплексной терапии дисфункций мочевого пузыря у женщин

Συγγραφείς: Зиятдинова, Г., Ниаури, Д., Седнев, О., Иванов, Л.

Θεματικοί όροι: ГИПЕРАКТИВНЫЙ МОЧЕВОЙ ПУЗЫРЬ,АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ,ЭЛЕКТРОСТИМУЛЯЦИЯ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/patogeneticheskoe-znachenie-transkranialnoy-elektrostimulyatsii-v-kompleksnoy-terapii-disfunktsiy-mochevogo-puzyrya-u-zhenschin-1
http://cyberleninka.ru/article_covers/15069851.png

Клиническая фармакология антихолинергических препаратов

Πηγή: Практическая пульмонология.

Θεματικοί όροι: АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ,БРОНХИАЛЬНАЯ АСТМА,ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/15719028.png
http://cyberleninka.ru/article/n/klinicheskaya-farmakologiya-antiholinergicheskih-preparatov-1

Современный взгляд на включение антихолинергических препаратов в состав премедикации

Πηγή: Анестезиология и реаниматология.

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, АНТИХОЛИНЕРГИЧЕСКИЕ ПРЕПАРАТЫ, АТРОПИН, ПРЕМЕДИКАЦИЯ, БРАДИКАРДИЯ, НАРУШЕНИЯ СЕРДЕЧНОГО РИТМА, САЛИВАЦИЯ, АNTICHOLINERGICS, 3. Good health

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article_covers/15797263.png
http://cyberleninka.ru/article/n/sovremennyy-vzglyad-na-vklyuchenie-antiholinergicheskih-preparatov-v-sostav-premedikatsii